@article {VI{\~N}A-ROMERO2419, author = {MICAELA M. VI{\~N}A-ROMERO and RUTH RAMOS-DIAZ and IVETTE MOURANI-PADRON and HECTOR GONZALEZ-MENDEZ and MACARENA GONZALEZ-CRUZ and GLORIA JULIA NAZCO-CASARIEGO and JAVIER F. MERINO-ALONSO and JESICA DIAZ-VERA and FERNANDO GUTI{\'E}RREZ-NICOL{\'A}S}, title = {Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials}, volume = {34}, number = {5}, pages = {2419--2421}, year = {2020}, doi = {10.21873/invivo.12055}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the leftover is usually discarded. The aim of this study will be to analyse the stability of the reconstituted lyophilised ERW-ASNase. Materials and Methods: In the present study, we analysed the enzymatic stability of reconstituted ERW-ASNase after conservation in three different temperature conditions for 2 and 5 days. Results: Our results show that ERW-ASNase is stable at 4{\textdegree}C, -20{\textdegree}C and -80{\textdegree}C for up to 5 days, retaining 95\% of the initial enzymatic activity in all three storage temperatures tested. Conclusion: It is feasible to reuse the remaining content of ERW-ASNase vial after reconstitution, which allows the optimization of the content of ERW-ASNase vials use and reduces the cost of this formulation usage, making it more accessible.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/34/5/2419}, eprint = {https://iv.iiarjournals.org/content/34/5/2419.full.pdf}, journal = {In Vivo} }